NAPSRX STUDY GUIDE

NAPSRX STUDY GUIDE


Pharmaceuticalsvg-vganswer--
Medicinesvgandvgvaccinesvgforvghumanvgandvganimalvguse.vgProductsvgmayvghavevgavgtrad
emarkvg(brand)vgnamevgorvgbevggeneric;vgandvgtheyvgmayvgbevgprescriptionvgorvgover-
thevgcounter.

Diagnosticvg-vganswer--
Equipmentvgandvgsuppliesvgusedvginvgscreening,vgdetecting,vgandvgmonitoringvgdisease.vg
Canvgrangevgfromvgsimplevghomevgtestingvgkitsvgtovgsophisticatedvgdiagnosticvgimagingvgte
chnologies.

MedicalvgDevicesvg-vganswer--
Advancedvginstrumentationvgandvgappliancesvgusedvgforvgmedicalvgtherapy,vgsuchvgasvgjoi
ntvgreplacements,vgimplantablevgdefibrillators,vgandvgpacemakers.vgAlsovgincludesvgdrugv
gdeliveryvgdevicesvgsuchvgasvgsyringes,vginfusionvgpumps,vgmetered-

dosevginhalers,vgandvgtransdermalvgpatches.

MedicalvgSuppliesvg-vganswer--Commodity,vghigh-
volumevgsuppliesvgsuchvgasvgsurgicalvggownsvgandvggloves.

DurablevgMedicalvgEquipmentvg-vganswer--Reusablevgproductsvgforvghealth-
relatedvgusevginvgthevghome,vgsuchvgasvgwalkers,vgwheelchairs,vgoxygenvgequipment,vgpro
stheticsvgandvghospitalvgbeds.

Whatvgcountriesvgarevgpharmaceuticalvgsalesvgthevghighest?vg-vganswer--
UnitedvgStates,vgWesternvgEurope,vgandvgJapan.

ThevgU.S.vgaccountsvgforvgroughlyvg__________vgofvgthevgworld'svgpharmaceuticalvgreven
ues.vg-vganswer--50%

Twovgfactorsvghavevgsignificantlyvgcontributedvgtovgrecentvggrowthvginvgthevgpharmaceutic
alvgindustryvgare?vg-vganswer--Populationvggrowthvgandvgincreasingvglifevgexpectancies.

Whatvgisvgthevgpredictedvgrelationshipvgbetweenvgpharmaceuticalvgcompaniesvgandvggen
omicvgresearchvgfacilities?vg-vganswer--
Partnershipsvgbetweenvgpharmaceuticalvgcompaniesvgandvggenomicvgresearchvgfacilitie
svgwillvgnotvgprovevgimmediatelyvgprofitable.

Prescriptionvgdrugvgtherapyvgisvgcostvgeffectivevgforvginsurancevgcompaniesvgandvghealthvg
carevgproviders.vgTruevgorvgFalse?vg-vganswer--True

Thevghighvgpricevgofvghealthvgcarevgisvgexplainedvgbyvgthevghighvgpricevgofvgmedicines.vgTru
evgorvgFalse?vg-vganswer--False

,OnevgofvgthevgoldestvgandvgleastvgeffectivevgpharmaceuticalvgmarketingvgtechniquesvgisvgD
TCvg(direct-to-consumer)vgadvertising.vgTruevgorvgFalse?vg-vganswer--False

Whatvginfluencesvgthevgnumbervgofvgdistrictsvginvgavgregion?vg-vganswer--
Thevgregion'svgpopulation.

Whatvgisvganvgexamplevgofvgthevgregionalizationvgofvghealthcarevgdeliveryvgsystems?vg-
vganswer--

CaliforniavgandvgFloridavghavevgdifferentvgprescriptionvgreimbursementvgpolicies.

Whatvgisvgthevgheartvgofvgavgpharmaceuticalvgsalesvgteam?vg-vganswer--DistrictvgManager.

Howvgmanyvgterritoriesvgarevginvgavgtypicalvgdistrict?vg-vganswer--8-12

Whatvgisvgthevgmostvgeffectivevgmethodvgforvggrabbingvgmarketvgshare?vg-vganswer--
Comparativevgselling.

Thevgaveragevgreviewvgtimevgforvgavgnewvgdrugvgisvg18vgmonths,vgdownvgfromvgalmostvg3vgy
earsvginvg1996.vgTruevgorvgFalse?vg-vganswer--True

Whatvgarevgsomevgquestionsvgrepsvgshouldvgaskvgavgphysician?vg-vganswer--
Whyvgdovgyouvgprefervgthevgcompetitor'svgdrugvgtovgours?
vgWhatvgdovgtheyvglikevgandvgdislikevgaboutvgit?

vgWhichvgpatientvgtypesvgisvgthevgdrugvgbeingvgusedvgfor?

vgWhatvgarevgthevgresultsvgandvgsidevgeffects,vgifvgany?vg



Note:vgCarefulvgquestioningvgandvglisteningvgenablesvgrepsvgtovgcraftvgeffectivevgmessage
svgbasedvgonvgeachvgphysician'svgspecificvgneeds.

Pharmaceuticalvgrepsvgmainlyvgvisitvgpharmacies.vgTruevgorvgFalse?vg-vganswer--
False.vgPharmaceuticalvgrepsvgmainlyvgvisit/targetvgphysicians.

Itvgusuallyvgtakesvgonlyvg1-
2vgcallsvgonvgavgphysicianvgbeforevghevgorvgshevgprescribesvgyourvgproduct.vgTruevgorvgFals
e?vg-vganswer--
False.vgYourvgsuccessvgultimatelyvgdependsvgonvgyourvgrelationshipvgwithvgthevgphysician.
vgThisvgtakesvgtime.vgPersistencevgisvgkey.



Thevgpharmacistvgmayvgdispensevgavgproductvgothervgthanvgwhatvgthevgphysicianvgprescri
bed.vgTruevgorvgFalse?vg-vganswer--
True.vgThevgpharmacistvgcanvgeithervg(1)vgdispensevgavggeneric;vg(2)vgThevgpharmacistvgc
allsvgthevgdoctorvgandvgrequestsvgpermissionvgtovgdispensevgavgdifferentvgmedication.

Accordingvgtovgchaptervg2vgofvgyourvgmanualvgwhichvgofvgthevgfollowingvgclassifiesvgasvgpay
ers?vg
(a)vgemployers
(b)vgpatientsvg
(c)vgpharmacists
(d)vgphysiciansvg-vganswer--(a)vgemployersvg

, Somevgthirdvgpartyvgpayersvgincludevgthevginsurancevgcompany,vgthevgemployer,vgmanag
edvgcarevgorganization,vgorvgthevgU.S.vggovernmentvg(Medicare/Medicaid).

Whatvgdefinesvgethicalvgpharmaceuticalvgcompanies?vg-vganswer--
Pharmaceuticalvgcompaniesvgthatvgresearchvgandvgdevelopvgnovelvgdrugs.

ThanksvgtovgmodernvgmedicinevghowvglongvgarevgpeoplevgnewlyvgdiagnosedvgwithvgHIVvge
xpectedvgtovglive?vg-vganswer--Anothervg50vgyears.

HowvgmuchvghasvgthevgaveragevgAmericanvglifespanvgincreasedvgsincevg1890?vg-
vganswer--30vgyears



Whatvgisvgavgtreatmentvggroup?vg-vganswer--
Avggroupvgofvgpatientsvgassignedvgtovgreceivevgspecificvgtreatment.

Whatvgisvgthevgmainvgdifferencevgbetweenvgavgblindedvgandvgdouble-blindedvgstudy?vg-
vganswer--

Invgavgdoublevgblindedvgstudy,vgneithervgthevgstaffvgnorvgthevgstudyvgparticipantsvgknowvgwh
ichvgsubjectsvgarevginvgthevgexperimentalvggroupvgandvgwhichvgsubjectsvgarevginvgthevgcontr
olvggroup.

Whatvgdoesvgasymptomaticvgmean?vg-vganswer--
Withoutvgsignsvgorvgsymptomsvgofvgdisease.

Whatvgisvganvgapprovablevgletter?vg-vganswer--
LettersvgsentvgbyvgthevgFDAvgtovgthevgapplicantvgindicatingvgwhethervgthevgnewvgdrugvgappl
icationvg(NDA)vgorvgabbreviatedvgnewvgdrugvgapplicationvg(ANDA)vgforvgavgproductvgmeets
vgthevgnecessaryvgrequirementsvgandvgwhethervgorvgnotvgthevgagencyvgbelievesvgthatvgitvgc

anvgapprovevgthevgapplicationvgorvgabbreviatedvgapplicationvgifvgspecificvgadditionalvginfor
mationvgorvgmaterialvgisvgsubmittedvgorvgspecificvgconditionsvg(e.g.,vgcertainvgchangesvginvg
labeling)vgarevgagreedvgtovgbyvgthevgapplicant.

Whatvgisvgavgblindedvgorvgmaskedvgstudy?vg-vganswer--
Avgstudyvginvgwhichvgparticipantsvgdovgnotvgknowvgwhethervgtheyvgarevginvgthevgexperiment
alvgorvgcontrolvggroupvgofvgavgresearchvgstudy.vgThosevginvgthevgexperimentalvggroupvggetvgt
hevgmedicationsvgorvgtreatmentsvgbeingvgtested,vgwhilevgthosevginvgthevgcontrolvggroupvgge
tvgstandardvgtreatmentvgorvgnovgtreatment.

Whatvgisvgavgcontrolvgorvgcontrolvggroup?vg-vganswer--
Thevgstandardvgbyvgwhichvgexperimentalvgobservationsvgarevgevaluated.vgInvgmanyvgclinic
alvgtrials,vgonevggroupvgofvgpatientsvgwillvgbevggivenvganvgexperimentalvgdrugvgorvgtreatment
,vgwhilevgthevgcontrolvggroupvgisvggivenvgeithervgavgstandardvgtreatmentvgforvgthevgillnessvgor
vgavgplacebo.



Whatvgisvgavgdouble-blindvgorvgdouble-maskedvgstudy?vg-vganswer--
Avgstudyvginvgwhichvgneithervgthevgparticipantsvgnorvgthevgstudyvgstaffvgknowvgwhichvgpartici
pantsvgarevgreceivingvgthevgexperimentalvgtreatmentvgandvgwhichvgpatientsvgarevginvgthevgc
ontrolvggroup.vgThesevgstudiesvgarevgperformedvgsovgneithervgthevgpatientvgnorvgdoctorvgex
pectationsvgaboutvgthevgexperimentalvgdrugvgcanvginfluencevgthevgoutcome.